{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', '3.', 'TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF', 'FIGURES', '1.', 'TITLE PAGE', '1', 'Substitution of Text after the Approval of BCX7353', '2', '1.1.', 'Protocol Approval Signature Page', '4', '1.2.', 'Clinical Study Protocol Agreement', '5', '2.', 'SYNOPSIS', '6', '3.', 'TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF FIGURES', '17', 'LIST OF TABLES', '22', 'LIST OF FIGURES', '23', '4.', 'LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS', '24', '5.', 'INTRODUCTION', '27', '5.1.', 'Background', '27', '5.2.', 'Nonclinical Findings for BCX7353', '27', '5.3.', 'Clinical Findings for BCX7353', '28', '5.3.1.', 'Summary of Study BCX7353-302', '29', '5.3.2.', 'Summary of Study BCX7353-203', '30', '5.3.3.', 'Data Monitoring Committee Review of Ongoing Studies BCX7353-302 and', 'BCX7353-204', '31', '5.4.', 'Rationale for Study', '31', '5.4.1.', 'Rationale for Study Design', '31', '5.4.2.', 'Rationale for BCX7353 Doses and Regimen', '32', '5.4.3.', 'Rationale for Study Population', '33', '5.4.4.', 'Rationale for Control Group and Prohibition of Current Prophylactic', 'Medications', '33', '5.4.5.', 'BCX7353 Benefit-Risk Analysis', '34', '5.4.6.', 'Benefits of Trial Participation', '35', '5.4.7.', 'Overall Benefit-Risk Assessment', '35', '6.', 'TRIAL OBJECTIVES', '35', '6.1.', 'Objectives', '35', '6.1.1.', 'Part 1 Primary Objective', '35', '6.1.2.', 'Part 1 Secondary Objectives', '35', '6.1.3.', 'Part 2 Primary Objective', '35', '17']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', '6.1.4.', 'Part 2 Secondary Objectives', '35', '6.1.5.', 'Part 3 Primary Objectives', '36', '6.1.6.', 'Part 3 Secondary Objectives', '36', '7.', 'OVERALL STUDY DESIGN AND PLAN', '36', '7.1.', 'Endpoints', '40', '7.1.1.', 'Part 1 Primary Efficacy Endpoint', '40', '7.1.2.', 'Part 1 Secondary Efficacy Endpoints', '40', '7.1.3.', 'Part 1 Exploratory Efficacy Endpoints', '40', '7.1.4.', 'Part 1 Safety Endpoints', '40', '7.1.5.', 'Part 1 Health Outcome Endpoints', '40', '7.1.6.', 'Part 2 Primary Endpoints', '41', '7.1.7.', 'Part 2 Secondary Endpoints', '41', '7.1.8.', 'Part 3 Primary Endpoints', '41', '7.1.9.', 'Part 3 Secondary Endpoints', '41', '8.', 'SELECTION AND WITHDRAWAL OF SUBJECTS', '42', '8.1.', 'Number of Subjects', '42', '8.2.', 'Subject Selection', '42', '8.2.1.', 'Inclusion Criteria', '42', '8.2.2.', 'Exclusion Criteria', '44', '8.3.', 'Subject Withdrawal from the Study and from Study Drug', '46', '8.3.1.', 'Subject Withdrawal from the Study', '46', '8.3.2.', 'Subject Discontinuation from Study Drug', '46', '8.4.', 'End of Study Definition', '47', '9.', 'TREATMENT OF SUBJECTS', '48', '9.1.', 'Description of Study Drug and Study Drug Product', '48', '9.2.', 'Description of Study Drug Packaging, Labeling, and Storage', '48', '9.3.', 'Randomization and Study Drug Blinding', '48', '9.3.1.', 'Blinding', '48', '9.3.2.', 'Randomization', '49', '9.3.2.1.', 'Part 1 Randomization', '49', '9.3.2.2.', 'Part 2 Randomization', '50', '9.4.', 'Study Drug Administration and Treatment Compliance', '51', '9.5.', 'Study Drug Dose Modification', '52', '18']\n\n###\n\n", "completion": "END"}